NASDAQ: NEOG · Life Sciences · 5 alerts · CIK 711377
Share price
$10.88Close, Nov 16
Market cap
$2.38B
Shares outstanding
218.31MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Neogen Corp filings on SEC EDGAR ↗
Jeremy Yarwood, CSO, sold 9,051 shares of Neogen Corp at $12.67 a share, worth $115K in total on Nov 4, 2026. Shares held after the trade: 0 (-100.0%).
Neogen Corporation provided a status update on the pending sale of its global Genomics business to Zoetis Inc. To facilitate regulatory clearance from the ACCC and NZCC, Zoetis has offered to divest certain assets in Australia, with the transaction now expected to close in early 2027.
Neogen Corporation's shareholders approved the Amended and Restated Omnibus Incentive Plan at the annual meeting held on October 1, 2026. The plan authorizes the issuance of up to 31,350,000 shares for various equity-based awards, including stock options and restricted stock units, for employees and non-employee directors. This filing amends a previous 8-K to specifically include the disclosure of this shareholder approval.
Neogen Corporation held its 2026 Annual Meeting of Shareholders on October 1, 2026, where shareholders elected three directors and ratified BDO USA, P.C. as the independent auditor for fiscal 2027. Shareholders also approved an advisory vote on executive compensation and authorized amendments to both the Omnibus Incentive Plan and the Employee Stock Purchase Plan, including an increase in shares available for issuance.
Neogen Corporation reported first-quarter fiscal 2027 revenue of $222.8 million, a 6.5% increase year-over-year, driven by strong growth in its Food Safety segment. Despite a net loss of $11.9 million, the company raised its full-year 2027 guidance for both revenue and Adjusted EBITDA based on encouraging operational progress.
Term
Q1 2027
Earnings call
Oct 6, 2026, 4:30 PM ET
“As we entered fiscal year 2027, our focus shifted from strengthening fundamentals to scaling them to drive more consistent execution, improved customer outcomes and profitable growth.”
Mike Nassif, Neogen’s President and Chief Executive Officer
“Our first-quarter results reflect encouraging progress as the changes underway across the organization continue to take hold.”
Mike Nassif, Neogen’s President and Chief Executive Officer